Table 1.
Type of systemic therapies employed as the immediate subsequent therapeutic line after TREnd (physician choice), classified by pharmacological classes
| Number | ||
|---|---|---|
| Subsequent chemotherapy (n = 69, 66%) | ||
| Capecitabine-containing (n = 30) | Capecitabine | 22 |
| Capecitabine + vinorelbine | 6 | |
| Capecitabine + vinorelbine + cyclophosphamide | 2 | |
| Taxane-based (n = 21) | Paclitaxel | 20 |
| Paclitaxel + BYL79* | 1 | |
| Anthracycline-based (n = 9) | Doxorubicin | 1 |
| Epirubicin | 1 | |
| Doxorubicin + cyclophosphamide | 7 | |
| Platinum-containing (n = 2) | Cisplatin | 1 |
| Cisplatin + cyclophosphamide | 1 | |
| Others (n = 7) | Vinorelbine | 3 |
| Cyclophosphamide + methotrexate | 2 | |
| Cyclophosphamide + vinorelbine | 2 | |
| Subsequent endocrine therapy (n = 33, 31%) | ||
| Fulvestrant (n = 20) | 20 | |
| AIs (n = 7) | Letrozole | 2 |
| Anastrozole | 1 | |
| Exemestane | 4 | |
| AI + mTORi (n = 6) | Exemestane + everolimus | 5 |
| Exemestane + everolimus + BYL719* | 1 | |
| Subsequent other targeted/novel therapies (n = 3, 3%) | ||
| Lucitanib | 1 | |
| Ribociclib (single agent) | 1 | |
| 64-Cu-asparagine | 1 | |
AIs aromatase inhibitors, mTORi inhibitors of mammalian target of rapamycin
*BYL719 = alpelisib (PI3K inhibitor)